SSY Group (02005.HK): Ziprasidone Mesylate Approved as API for Use in Marketed Formulations

Zhitong Finance APP News, SSY Group (02005.HK) announced that the Group's ziprasidone mesylate has been approved by China's National Medical Products Administration for registration as an active pharmaceutical ingredient for use in marketed formulations. Ziprasidone mesylate is mainly used for the treatment of acute agitation symptoms in patients with schizophrenia.